In a unanimous decision, the U.S. Supreme Court has ruled that generic pharmaceutical manufacturers, such as Hikma Pharmaceuticals USA, cannot be held liable for infringements of a branded manufacturer’s patents based on decisions made by doctors and pharmacies. The ruling came in the Hikma Pharmaceuticals USA v. Amarin Pharma Inc. case, where the central issue was whether Hikma could be held responsible for the use of its generic version of the drug Vascepa, a substitute for Amarin’s product, for patented uses despite the existence of non-patented alternatives.
This judicial stance was outlined in Justice Ketanji Brown Jackson’s opinion, which dismissed the assertion that Hikma had actively induced patent infringement. The judgment held that Hikma’s statements through labels, press releases, and website descriptions did not rise to the level of encouraging patent infringement. Justice Jackson highlighted that Hikma’s actions were in compliance with existing legal and industry standards. The statute underpinning this decision requires explicit proof of “actively induc[ing] infringement,” as set out in prior case law, referencing the MGM Studios, Inc. v. Grokster precedent.
This decision is notable for its implication on the pharmaceutical industry, especially in cases where generic drugs are used interchangeably for both patented and non-patented indications, such as Vascepa’s cardiovascular use and its severe hypertriglyceridemia indication. Given this ruling, manufacturers of generic medications are reaffirmed of their compliance duty without fear of undue legal backlash for third-party actions.
The court’s decision also reflects a broader reluctance to impose liability on companies for actions taken by third parties, similar to recent decisions, such as in Cox v. Sony. This approach underscores the requirement for clear evidence of deliberate inducement, maintaining a legal distinction between intentional infringement and unintentional conduct facilitated by standard industry practice.
For further details, refer to the full article on SCOTUSblog.